Greenwich LifeSciences, Inc. (GLSI)
16.03
+0.55
(+3.55%)
USD |
NASDAQ |
Oct 23, 16:00
16.07
+0.04
(+0.25%)
After-Hours: 20:00
Greenwich LifeSciences Enterprise Value : 226.42M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 226.42M |
| October 22, 2026 | 218.34M |
| October 21, 2026 | 234.34M |
| October 20, 2026 | 229.50M |
| October 19, 2026 | 214.38M |
| October 16, 2026 | 204.69M |
| October 15, 2026 | 215.99M |
| October 14, 2026 | 217.17M |
| October 13, 2026 | 218.64M |
| October 12, 2026 | 251.96M |
| October 09, 2026 | 233.75M |
| October 08, 2026 | 213.35M |
| October 07, 2026 | 217.02M |
| October 06, 2026 | 222.89M |
| October 05, 2026 | 239.33M |
| October 02, 2026 | 240.36M |
| October 01, 2026 | 245.79M |
| September 30, 2026 | 256.07M |
| September 29, 2026 | 260.91M |
| September 28, 2026 | 263.99M |
| September 25, 2026 | 258.56M |
| September 24, 2026 | 256.80M |
| September 23, 2026 | 248.14M |
| September 22, 2026 | 277.05M |
| September 21, 2026 | 264.06M |
| Date | Value |
|---|---|
| September 18, 2026 | 269.86M |
| September 17, 2026 | 261.06M |
| September 16, 2026 | 220.54M |
| September 15, 2026 | 227.30M |
| September 14, 2026 | 226.71M |
| September 11, 2026 | 217.90M |
| September 10, 2026 | 212.18M |
| September 09, 2026 | 211.74M |
| September 08, 2026 | 224.51M |
| September 04, 2026 | 225.24M |
| September 03, 2026 | 220.54M |
| September 02, 2026 | 222.16M |
| September 01, 2026 | 211.44M |
| August 31, 2026 | 210.56M |
| August 28, 2026 | 221.13M |
| August 27, 2026 | 266.05M |
| August 26, 2026 | 258.71M |
| August 25, 2026 | 263.99M |
| August 24, 2026 | 249.17M |
| August 21, 2026 | 235.81M |
| August 20, 2026 | 215.85M |
| August 19, 2026 | 245.64M |
| August 18, 2026 | 244.47M |
| August 17, 2026 | 246.23M |
| August 14, 2026 | 237.72M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 534.42M |
| Amgen, Inc. | 280.78B |
| Anika Therapeutics, Inc. | 273.50M |
| BioCryst Pharmaceuticals, Inc. | 2.436B |
| Imunon, Inc. | 6.743M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.949M |
| Total Expenses (Quarterly) | 3.949M |
| EPS Diluted (Quarterly) | -0.2701 |
| Earnings Yield | -9.46% |
| Normalized Earnings Yield | -9.463 |